You just read:

Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association

News provided by

Viking Therapeutics, Inc.

Oct 23, 2017, 07:05 ET